Beta-3 Adrenoceptors as New Therapeutic Targets for Cardiovascular Pathologies

Current Heart Failure Reports

Volumn 8, Issue 3, 2011, Pages 184-192

  Gauthier, Chantal ^a,b,c   Rozec, Bertrand ^a,b,c,d   Manoury, Boris ^e   Balligand, Jean Luc ^e  

^a L INSTITUT DU THORAX   (France)

^b CNRS ERL3147   (France)

^c UNIVERSITÉ DE NANTES   (France)

^d NANTES UNIVERSITY HOSPITAL   (France)

^e UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Adrenergic receptor; cAMP; Cardiomyocytes; Catecholamine; cGMP; Contractility; Cyclic adenosine monophosphate; Cyclic guanosine monophosphate; Diabetes; Electrophysiology; Excitation contraction coupling; Heart; Heart failure; Hypertension; Messenger RNA; mRNA; Myocardial infarction; Nebivolol; Nitric oxide; Nitric oxide synthase; NO; NOS; Remodeling; Ventricular remodeling; Vessels; blocker

Indexed keywords

4 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL]PHENOXYACETIC ACID; ANTIDEPRESSANT AGENT; BETA 3 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL L TYPE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ISOPRENALINE; MESSENGER RNA; METOPROLOL; MIRABEGRON; NEBIVOLOL; NITRIC OXIDE SYNTHASE; SOLABEGRON; SR 58611 A; UNCLASSIFIED DRUG;

AGING; ARTICLE; BLOOD VESSEL; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; EXCITATION CONTRACTION COUPLING; GENE CONTROL; GENETIC POLYMORPHISM; HEART ARRHYTHMIA; HEART ELECTROPHYSIOLOGY; HEART FAILURE; HEART HYPERTROPHY; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERTENSION; HYPOTHYROIDISM; LIVER CIRRHOSIS; MAJOR DEPRESSION; NONHUMAN; OVERACTIVE BLADDER; PROTEIN EXPRESSION; PROTEIN FUNCTION; SEPSIS; UNSPECIFIED SIDE EFFECT; VASODILATATION;

EID: 80055060619     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-011-0064-6     Document Type: Article

References (51)

1. Vrydag W, Michel MC. Tools to study beta3-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol. 2007;374:385-398.
2. Ursino MG, Vasina V, Raschi E, et al. The beta3-adrenoceptor as a therapeutic target: current perspectives. Pharmacol Res. 2009; 59:221-234.
3. Rozec B, Erfanian M, Laurent K, et al. Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart. J Am Coll Cardiol 2009;53:1532-1538.
4. Dessy C, Saliez J, Ghisdal P, et al. Endothelial beta3- adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation betablocker nebivolol. Circulation. 2005;112:1198-1205. (Pubitemid 41216127)
5. Tran Quang T, Rozec B, Audigane L, Gauthier C. Investigation of the different adrenoceptor targets of nebivolol enantiomers in rat thoracic aorta. Br J Pharmacol. 2009;156:601-608.
6. Candelore MR, Deng L, Tota L, et al. Potent and selective human beta(3)-adrenergic receptor antagonists. J Pharmacol Exp Ther. 1999;290:649-655. (Pubitemid 29344558)
7. Audigane L, Kerfant BG, El Harchi A, et al. Rabbit, a relevant model for the study of cardiac beta 3-adrenoceptors. Exp Physiol. 2009;94:400-411.
8. Bundgaard H, Liu CC, Garcia A, et al. β(3) adrenergic stimulation of the cardiac Na+-K + pump by reversal of an inhibitory oxidative modification. Circulation. 2010;122:2699-2708.
9. Skeberdis VA, Gendviliene V, Zablockaite D, et al. beta3-adrenergic receptor activation increases human atrial tissue contractility and stimulates the L-type Ca2+ current. J Clin Invest. 2008;118:3219-3227.
10. 3-adrenoceptor activation increases force and Ca(2+) current at physiological temperature. Br J Pharmacol. 2011;162:823-839.
11. Rozec B, Gauthier C. beta3-adrenoceptors in the cardiovascular system: putative roles in human pathologies. Pharmacol Ther. 2006;111:652-673. (Pubitemid 44137382)
12. Dessy C, Balligand JL. Beta3-adrenergic receptors in cardiac and vascular tissues emerging concepts and therapeutic perspectives. Adv Pharmacol. 2010;59:135-163.
13. Barbier J, Mouas C, Rannou-Bekono F, Carré F. Existence of beta (3)-adrenoceptors in rat heart: functional implications. Clin Exp Pharmacol Physiol. 2007;34:796-798. (Pubitemid 47013488)
14. Angelone T, Filice E, Quintieri AM, et al. Beta3-adrenoceptors modulate left ventricular relaxation in the rat heart via the NOcGMP- PKG pathway. Acta Physiol (Oxf). 2008;193:229-239. (Pubitemid 351783190)
15. Casadei B. Beta 3-adrenoceptors modulate left ventricular relaxation in the rat heart via the NO-cGMP-PKG pathway. Acta Physiol (Oxf). 2008;193:203. (Pubitemid 351783196)
16. Mazza R, Angelone T, Pasqua T, Gattuso A. Physiological evidence for β3-adrenoceptor in frog (Rana esculenta) heart. Gen Comp Endocrinol. 2010;169:151-157.
17. Ufer C, Germack R. Cross-regulation between beta 1- and beta 3-adrenoceptors following chronic beta-adrenergic stimulation in neonatal rat cardiomyocytes. Br J Pharmacol 2009;158:300-313.
18. Kawano F, Tanihata J, Sato S, et al. Effects of dexamethasone on the expression of beta(1)-, beta (2)- and beta (3)-adrenoceptor mRNAs in skeletal and left ventricle muscles in rats. J Physiol Sci. 2009;59:383-390.
19. Boivin B, Vaniotis G, Allen BG, Hébert TE. G protein-coupled receptors in and on the cell nucleus: a new signaling paradigm? J Recept Signal Transduct Res. 2008;28:15-28. (Pubitemid 351588071)
20. Boivin B, Lavoie C, Vaniotis G, et al. Functional betaadrenergic receptor signalling on nuclear membranes in adult rat and mouse ventricular cardiomyocytes. Cardiovasc Res. 2006;71:69-78. (Pubitemid 43849672)
21. Vaniotis G, Del Duca D, Trieu P, et al. Nuclear β-adrenergic receptors modulate gene expression in adult rat heart. Cell Signal. 2011;23:89-98.
22. Xiao RP, Tomhave ED, Wang DJ, et al. Age-associated reductions in cardiac beta1- and beta2-adrenergic responses without changes in inhibitory G proteins or receptor kinases. J Clin Invest. 1998;101:1273-1282. (Pubitemid 28145243)
23. Chen Z, Miao G, Liu M, et al. Age-related up-regulation of beta3-adrenergic receptor in heart-failure rats. J Recept Signal Transduct Res. 2010;30:227-233.
24. Birenbaum A, Tesse A, Loyer X, et al. Involvement of beta 3-adrenoceptor in altered beta-adrenergic response in senescent heart: role of nitric oxide synthase 1-derived nitric oxide. Anesthesiology. 2008;109:1045-1053.
25. Zaugg M, Schaub MC. Beta3-adrenergic receptor subtype signaling in senescent heart: nitric oxide intoxication or "endogenous" beta blockade for protection? Anesthesiology. 2008;109:956-959.
26. Oliver E, Martí D, Montó F, et al. The impact of alpha1- adrenoceptors up-regulation accompanied by the impairment of beta-adrenergic vasodilatation in hypertension. J Pharmacol Exp Ther. 2009;328:982-990.
27. Guimarães S, Moura D. Vascular adrenoceptors: an update. Pharmacol Rev. 2001;53:319-356. (Pubitemid 32476119)
28. Chruscinski A, Brede ME, Meinel L, et al. Differential distribution of beta-adrenergic receptor subtypes in blood vessels of knockout mice lacking beta(1)- or beta(2)-adrenergic receptors. Mol Pharmacol. 2001;60:955-962. (Pubitemid 33027430)
29. Al Zubair K, Bexis S, Docherty JR. Relaxations to beta-adrenoceptor subtype selective agonists in wild-type and NOS-3-KO mouse mesenteric arteries. Eur J Pharmacol. 2008;587:216-223.
30. Figueroa XF, Poblete I, Fernández R, et al. NO production and eNOS phosphorylation induced by epinephrine through the activation of beta-adrenoceptors. Am J Physiol Heart Circ Physiol. 2009;297:H134-H143.
31. Trebicka J, Hennenberg M, Schulze Pröbsting A, et al. Role of beta3-adrenoceptors for intrahepatic resistance and portal hypertension in liver cirrhosis. Hepatology. 2009;50:1924-1935.
32. Mori A, Miwa T, Sakamoto K, et al. Pharmacological evidence for the presence of functional beta(3)-adrenoceptors in rat retinal blood vessels. Naunyn Schmiedebergs Arch Pharmacol. 2010;382:119-126.
33. Karadas B, Kaya T, Cetin M, et al. Effects of formoterol and BRL 37344 on human umbilical arteries in vitro in normotensive and pre-eclamptic pregnancy. Vascul Pharmacol. 2007; 46:360-366. (Pubitemid 46386498)
34. Hynes PG, Friel AM, Smith TJ, Morrison JJ. Beta-adrenoceptor subtype expression in human placenta and umbilical arteries in normal and preeclamptic pregnancies. Hypertens Pregnancy. 2008;27:169-181. (Pubitemid 351892687)
35. 3-adrenoceptor agonist. Eur J Pharmacol. 2011;654:86-91.
36. Sorrentino SA, Doerries C, Manes C, et al. Nebivolol exerts beneficial effects on endothelial function, early endothelial progenitor cells, myocardial neovascularization, and left ventricular dysfunction early after myocardial infarction beyond conventional β1- blockade. J Am Coll Cardiol 2011;57:601-611.
37. Zhou L, Zhang P, Cheng Z, et al. Altered circadian rhythm of cardiac β3-adrenoceptor activity following myocardial infarction in the rat. Basic Res Cardiol. 2011;106:37-50.
38. Zhou S, Jung BC, Tan AY, et al. Spontaneous stellate ganglion nerve activity and ventricular arrhythmia in a canine model of sudden death. Heart Rhythm. 2008;5:131-139.
39. Li H, Liu Y, Huang H, et al. Activation of β3-adrenergic receptor inhibits ventricular arrhythmia in heart failure through calcium handling. Tohoku J Exp Med. 2010;222:167-174.
40. Napp A, Brixius K, Pott C, et al. Effects of the beta3- adrenergic agonist BRL 37344 on endothelial nitric oxide synthase phosphorylation and force of contraction in human failing myocardium. J Card Fail 2009;15:57-67.
41. Balligand JL. beta(3)-Adrenoceptor stimulation on top of beta(1)- adrenoceptor blockade "Stop or Encore?". J Am Coll Cardiol. 2009;53:1539-1542.
42. Berg T, Piercey BW, Jensen J. Role of beta1-3-adrenoceptors in blood pressure control at rest and during tyramine-induced norepinephrine release in spontaneously hypertensive rats. Hypertension. 2010;55:1224-1230.
43. Mallem MY, Toumaniantz G, Serpillon S, et al. Impairment of the low-affinity state beta1-adrenoceptor-induced relaxation in spontaneously hypertensive rats. Br J Pharmacol. 2004;143:599-605. (Pubitemid 39524277)
44. Feldman RD, Gros R. Defective vasodilatory mechanisms in hypertension: a G-protein-coupled receptor perspective. Curr Opin Nephrol Hypertens. 2006;15:135-140.
45. Pettersson US, Henriksnäs J, Jansson L. Reversal of high pancreatic islet and white adipose tissue blood flow in type 2 diabetic GK rats by administration of the beta3-adrenoceptor inhibitor SR-59230A. Am J Physiol Endocrinol Metab. 2009;297: E490-E494.
46. Le Douairon Lahaye S, Rebillard A, Zguira MS, et al. Effects of exercise training combined with insulin treatment on cardiac NOS1 signaling pathways in type 1 diabetic rats. Mol Cell Biochem. 2011;347:53-62.
47. Arioglu E, Guner S, Ozakca I, et al. The changes in betaadrenoceptor- mediated cardiac function in experimental hypothyroidism: the possible contribution of cardiac beta3-adrenoceptors. Mol Cell Biochem. 2010;335:59-66.
48. Moniotte S, Belge C, Sekkali B, et al. Sepsis is associated with an upregulation of functional beta3 adrenoceptors in the myocardium. Eur J Heart Fail. 2007;9:1163-1171. (Pubitemid 350148276)
49. Vrydag W, Alewijnse AE, Michel MC. Do gene polymorphisms alone or in combination affect the function of human beta3-adrenoceptors? Br J Pharmacol. 2009;156:127-134.
50. Zafarmand MH, van der Schouw YT, Grobbee DE, et al. T64A polymorphism in beta3-adrenergic receptor gene (ADRB3) and coronary heart disease: a case-cohort study and meta-analysis. J Intern Med. 2008;263:79-89. (Pubitemid 350243548)
51. Moniotte S, Kobzik L, Feron O, Trochu JN, Gauthier C, Balligand JL. Upregulation of beta(3)-adrenoceptors and altered contractile response to inotropic amines in human failing myocardium. Circulation. 2001;103(12):1649- 1655. (Pubitemid 32246612)